long intergenic non-protein coding RNA 1625Genealiases: []
Q-omics provides the consensus-scored LINC01625 profile across patient tissues and cancer cell-line models. LINC01625 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC01625 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, LINC01625 RNA expression shows 14,046 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, THCA, and LSCC as cancer lineages where LINC01625 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01625 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01625 survival associations across molecular data types. LINC01625 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01625 RNA expression–survival associations across cancer types. High LINC01625 expression shows unfavorable associations in BLCA, UCEC, CHOL, THCA and KICH, but favorable associations in KIRP. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC01625 RNA expression.
This table summarizes LINC01625 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01625. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01625 shows lower tumor expression in THCA, LUAD, KICH, KIRP, KIRC and LUSC. The THCA box plot shows higher LINC01625 RNA expression in normal versus tumor tissue (log2 FC = −0.580, t-test p < 0.001).
This table shows molecular features associated with LINC01625 in patient tissues and cancer cell lines. In patient samples, LINC01625 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
